2023
Early Treatment for Multiple Sclerosis
Longbrake E, Kalincik T. Early Treatment for Multiple Sclerosis. Neurology 2023, 101: 549-550. PMID: 37468283, DOI: 10.1212/wnl.0000000000207754.Peer-Reviewed Original ResearchMeSH KeywordsBrainHeadHumansMagnetic Resonance ImagingMultiple SclerosisMultiple Sclerosis, Relapsing-Remitting
2022
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
Freeman L, Longbrake E, Coyle P, Hendin B, Vollmer T. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis. CNS Drugs 2022, 36: 1285-1299. PMID: 36350491, PMCID: PMC9645316, DOI: 10.1007/s40263-022-00965-7.Peer-Reviewed Original ResearchMeSH KeywordsAlemtuzumabHumansImmunologic FactorsMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingNatalizumabConceptsRelapsing-remitting multiple sclerosisHigh-efficacy therapiesMultiple sclerosisClinical benefitEarly treatmentRecent international consensus guidelinesLong-term clinical outcomesAvailable treatment optionsInternational consensus guidelinesTreatment-naïve individualsMechanism of actionDMT optionsMS careDisease courseClinical outcomesConsensus guidelinesTherapy optionsTreatment optionsNeurological damageTreatment strategiesEscalation approachClinical practiceUS FoodDrug AdministrationPatients
2020
Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity
Longbrake EE, Mao-Draayer Y, Cascione M, Zielinski T, Bame E, Brassat D, Chen C, Kapadia S, Mendoza JP, Miller C, Parks B, Xing D, Robertson D. Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity. Multiple Sclerosis Journal 2020, 27: 883-894. PMID: 32716690, PMCID: PMC8023410, DOI: 10.1177/1352458520937282.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Inflammatory AgentsDimethyl FumarateHumansImmunity, HumoralImmunosuppressive AgentsMultiple Sclerosis, Relapsing-RemittingNeoplasm Recurrence, LocalProspective StudiesConceptsDelayed-release dimethyl fumarateAbsolute lymphocyte countT cellsMedian absolute lymphocyte countEffector memory T cellsDimethyl fumarate treatmentPhase 3b studyTotal T cellsAdverse event ratesMemory T cellsProtective humoral immunityForms of MSDMF BIDLymphocyte subsetsAdverse eventsLymphocyte countTotal IgAImmune environmentImmunoglobulin levelsNaive CD4Sustained efficacyHumoral immunityFumarate treatmentSubclass levelsCount changes
2017
Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count
Longbrake EE, Cantoni C, Chahin S, Cignarella F, Cross AH, Piccio L. Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count. Multiple Sclerosis Journal 2017, 24: 728-738. PMID: 28480794, PMCID: PMC5665729, DOI: 10.1177/1352458517707069.Peer-Reviewed Original ResearchMeSH KeywordsAdultB-LymphocytesCross-Sectional StudiesDimethyl FumarateFemaleHumansImmunosuppressive AgentsLymphocyte CountLymphopeniaMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingT-LymphocytesConceptsAbsolute lymphocyte countDMF-treated patientsPeripheral blood mononuclear cellsDimethyl fumarateLymphocyte countPeptide stimulationLow absolute lymphocyte countFollicular T helper cellsDMF-induced lymphopeniaInvariant T (MAIT) cellsPro-inflammatory cytokinesT-cell phenotypeBlood mononuclear cellsT cell productionT helper cellsT lymphocyte functionMemory B cellsActivation-induced cell deathMultiparametric flow cytometryUntreated patientsMultiple sclerosisMononuclear cellsHealthy controlsT cellsT lymphocytes
2014
Dimethyl fumarate associated lymphopenia in clinical practice
Longbrake EE, Cross AH. Dimethyl fumarate associated lymphopenia in clinical practice. Multiple Sclerosis Journal 2014, 21: 796-797. PMID: 25432948, PMCID: PMC4426020, DOI: 10.1177/1352458514559299.Peer-Reviewed Original ResearchDimethyl FumarateHumansImmunosuppressive AgentsLeukoencephalopathy, Progressive MultifocalLymphopeniaMultiple Sclerosis, Relapsing-Remitting